Biotech Values

[DewDiligence]

Someone who hasn’t been following MNTA evidently thought this meant the generic-Copaxone program was dead. It isn’t, of course; the lack of a summary judgment in the patent litigation merely means that the case will go to trial. Moreover, as noted in my prior post, Teva’s Orange Book patents for Copaxone expire in 2014.